Related Experiment Video

Updated: Jan 23, 2026

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.4K

Stem cell therapy in heart failure: Where do we stand today?

Nandini Nair1, Enrique Gongora2

  • 1Division of Cardiology, Department of Medicine, Texas Tech Health Sciences Center, Lubbock, TX 79430, USA.

Biochimica Et Biophysica Acta. Molecular Basis of Disease
|June 15, 2019
PubMed

Insights

Stem cell therapy shows promise for heart failure (HF) treatment, particularly when combined with revascularization for ischemic cardiomyopathy. Further research is needed to optimize stem cell use in dilated cardiomyopathy and understand co-morbidities

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Biomedical Engineering

Background:

  • Heart failure (HF) is a global health crisis affecting millions worldwide, significantly reducing lifespan and quality of life.
  • Current HF treatments are etiology-dependent and, if untreated, lead to rapid disease progression.
  • Stem cell therapy represents an emerging, yet nascent, therapeutic strategy for managing heart failure.

Purpose of the Study:

  • To review and highlight clinical studies on stem cell therapy for various types of cardiomyopathy, including ischemic, dilated, and restrictive.
  • To assess the efficacy and potential benefits of stem cell interventions in different heart failure contexts.
  • To identify challenges and future research directions for optimizing stem cell therapy in cardiovascular disease.

Main Methods:

  • Review of clinical studies focusing on stem cell therapy in ischemic, dilated, and restrictive cardiomyopathy.
  • Analysis of combined approaches, such as simultaneous revascularization and stem cell administration.
  • Evaluation of factors influencing stem cell therapy outcomes, including cell type, delivery, timing, and patient co-morbidities.

Main Results:

  • A combined strategy of revascularization and stem cell therapy demonstrated maximum benefit in ischemic cardiomyopathy.
  • Stem cell treatment for dilated cardiomyopathy shows potential but requires further definition regarding delivery methods and cell types for reproducible results.
  • Patient co-morbidities, especially diabetes and glucose metabolism abnormalities, can impair stem cell mobilization and influence therapeutic efficacy.

Conclusions:

  • Stem cell therapy holds significant promise for treating heart failure, with combined approaches showing particular efficacy in ischemic cardiomyopathy.
  • Optimizing stem cell therapy for dilated cardiomyopathy necessitates further research into delivery routes, timing, and cell selection.
  • Investigating the biochemical microenvironment and its impact on stem cell function is crucial for enhancing treatment effectiveness and overcoming variability in patient responses.

Keywords:
AmyloidosisCardiomyopathyStem cell therapy

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
280
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
798
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.1K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
737
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
830
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
232